A single-cell-resolved ferroptosis gene signature with strong prognostic and therapeutic implications for ESCC is presented, showing that knockdown of CDCA3 lead to the downregulation of ferroptosis inhibitor-related genes and upregulation of ferroptosis-promoting genes, thereby enhancing the sensitivity to RSL3-induced ferroptosis.
Abstract
Background Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, plays a crucial role in tumor progression and immune regulation. Methods We integrated single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data to identify ferroptosis-active cellular subpopulations within the ESCC tumor microenvironment. A ferroptosis-related prognostic model was constructed using LASSO-Cox regression and validated across independent cohorts from TCGA and GEO. Associations with immune infiltration, tumor mutation burden, therapeutic response, and drug sensitivity were explored. Furthermore, functional experiments were conducted in vitro using the ESCC cell lines, and the four prognostic core genes were revalidated using an independent single-cell dataset, which was also fully confirmed in clinical ESCC tissue samples. In addition, Western blot analysis was performed to examine the expression levels of ferroptosis-related proteins following CDCA3 knockdown, and to further investigate the impact of CDCA3 depletion on the cellular response to the ferroptosis inducer RSL3. Results Four ferroptosis-related genes (CBS, CDCA3, GALNT14, and IDO1) were identified used to construct a robust risk model, effectively stratifying patients into high- and low-risk groups with significant differences in survival, immune infiltration, and predicted treatment response. In vitro experiments confirmed that CDCA3 knockdown significantly inhibited the proliferation and migration of ESCC cells and induced ferroptosis. GSE188900 single-cell sequencing data further confirmed that the aforementioned genes were significantly upregulated at single-cell resolution in tumor cells, with consistent validation in clinical ESCC tissue samples, Moreover,experimental results showed that knockdown of CDCA3 lead to the downregulation of ferroptosis inhibitor-related genes and upregulation of ferroptosis-promoting genes, thereby enhancing the sensitivity to RSL3-induced ferroptosis. Conclusions Our study presents a single-cell-resolved ferroptosis gene signature with strong prognostic and therapeutic implications for ESCC. The signature was validated in clinical tissue samples, and this model lays the foundation for ferroptosis-targeted therapeutic strategies.
GCLC and SLC1A5 emerged as TAM-related candidate genes that warrant further mechanistic and prospective validation and computationally predicted drug sensitivity and associations between TAMFGS and immune-related transcriptomic estimates and computationally predicted drug sensitivity are identified.
Yingjun Wang, Lai Wei, Jie-Ting Wang et al.· European Journal of Medical...· 0 citations
This study identifies TPI1 as a key tumor-promoting factor and independent prognostic biomarker in HNSCC, providing a promising therapeutic target for overcoming ferroptosis evasion in HNSCC.
Rui Ye, Zhihua Xu, Ye-Hai Liu· Frontiers in Genetics· 0 citations
Clinical, histopathological, and loss-of-function findings support further investigation of CARS1 as a prognostic marker and candidate therapeutic target in HCC, although additional mechanistic and in vivo validation is required.
Ye-Zhen Tang, Ke-Jun Liu, Zhen-Ya Tan et al.· Frontiers in Bioscience· 0 citations
PANX2 is identified as a ccRCC-relevant suppressor of ferroptosis and supports the involvement of a PANX2-Akt/mTOR-SLC7A11-associated signaling axis in redox homeostasis and tumor progression.
Xing-Lin Li, Yiqi Xiong, Ji-Yin Wang et al.· Frontiers in Immunology· 0 citations
CASC9 functions as an oncogenic lncRNA that promotes ESCC progression by modulating ferroptosis, representing a promising early diagnostic biomarker, prognostic predictor, and therapeutic target.
The findings demonstrate that MCs exhibit distinct functional states in ESCC and regulate tumor progression and support their potential relevance in immunotherapy.
Yiren Huang, Zheyi Chen, Bingqian Zhou et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.